$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

$sls Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000139047814000024 Filed on May 06, 2014

Income Statement

Concept	2014 Q2	2014 Q1	2013 Q1
Revenue	$2.331M	$2.173M	$2.750M
YoY Change	-31.08%	-20.98%	0.0%
Cost Of Revenue	$347.0K	$331.0K	$0.00
YoY Change
Gross Profit	$1.984M	$1.842M	$2.357M
YoY Change	-31.91%	-21.85%	0.0%
Gross Profit Margin	85.11%	84.77%	85.71%
Selling, General & Admin	$9.600M	$6.830M	$1.530M
YoY Change	254.24%	346.41%	-12.57%
% of Gross Profit	483.87%	370.79%	64.91%
Research & Development	$8.069M	$6.770M	$5.081M
YoY Change	52.94%	33.24%	90.73%
% of Gross Profit	406.7%	367.54%	215.57%
Depreciation & Amortization	$230.0K	$232.0K	$2.000K
YoY Change	475.0%	11500.0%	-95.24%
% of Gross Profit	11.59%	12.6%	0.08%
Operating Expenses	$17.67M	$13.60M	$6.611M
YoY Change	121.25%	105.72%	49.91%
Operating Profit	-$15.78M	-$11.85M	-$6.611M
YoY Change	97.63%	79.23%	222.02%
Interest Expense	-$3.670M	$9.480M	-$5.000M
YoY Change	2723.08%	-289.6%	-72.66%
% of Operating Profit
Other Income/Expense, Net	-$19.94M	-$2.536M	-$12.06M
YoY Change	147.53%	-78.96%	-36.98%
Pretax Income	-$15.95M	-$2.540M	-$12.06M
YoY Change	97.99%	-78.93%	-48.79%
Income Tax	$0.00	$0.00	-$2.762M
% Of Pretax Income
Net Earnings	-$19.94M	-$2.536M	-$16.49M
YoY Change	-470.03%	-84.62%	56.52%
Net Earnings / Revenue	-855.47%	-116.71%	-599.75%
Basic Earnings Per Share			-$1.84
Diluted Earnings Per Share	-$4.029B	-$654.5M	-$3.359B
COMMON SHARES
Basic Shares Outstanding	118.0M shares	117.9M shares	83.07M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q2	2014 Q1	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$39.20M	$52.40M	$27.19M
YoY Change	46.79%	92.72%	212.53%
Cash & Equivalents	$39.16M	$52.43M	$17.48M
Short-Term Investments			$9.709M
Other Short-Term Assets	$1.900M	$1.500M	$300.0K
YoY Change	280.0%	400.0%	-25.0%
Inventory	$433.0K	$358.0K
Prepaid Expenses
Receivables	$2.152M	$1.466M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$43.68M	$55.78M	$27.50M
YoY Change	58.57%	102.82%	202.22%
LONG-TERM ASSETS
Property, Plant & Equipment	$623.0K	$653.0K	$27.00K
YoY Change	33.4%	2318.52%	-93.25%
Goodwill	$5.898M	$5.898M	$5.898M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$100.0K	$100.0K	$100.0K
YoY Change	0.0%	0.0%
Total Long-Term Assets	$36.59M	$36.51M	$33.95M
YoY Change	6.21%	7.55%	77.74%
TOTAL ASSETS
Total Short-Term Assets	$43.68M	$55.78M	$27.50M
Total Long-Term Assets	$36.59M	$36.51M	$33.95M
Total Assets	$80.28M	$92.29M	$61.45M
YoY Change	29.47%	50.18%	117.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.036M	$1.574M	$2.123M
YoY Change	-2.68%	-25.86%	-18.35%
Accrued Expenses	$11.79M	$9.793M	$7.478M
YoY Change	39.61%	30.96%	113.66%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.076M	$3.102M	$0.00
YoY Change	1254.15%
Total Short-Term Liabilities	$33.41M	$26.84M	$26.38M
YoY Change	29.75%	1.75%	-3.73%
LONG-TERM LIABILITIES
Long-Term Debt	$6.003M	$6.883M	$100.0K
YoY Change	-36.16%	6783.0%	-90.0%
Other Long-Term Liabilities	$7.500M	$7.000M	$6.700M
YoY Change	15.38%	4.48%	26.42%
Total Long-Term Liabilities	$6.003M	$6.883M	$6.800M
YoY Change	-36.16%	1.22%	7.94%
TOTAL LIABILITIES
Total Short-Term Liabilities	$33.41M	$26.84M	$26.38M
Total Long-Term Liabilities	$6.003M	$6.883M	$6.800M
Total Liabilities	$51.97M	$45.79M	$38.14M
YoY Change	11.11%	20.05%	-1.7%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock	$233.5M	$231.8M	$132.8M
YoY Change	70.88%	74.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$3.849M	$3.849M	$3.849M
YoY Change	0.0%	0.0%
Treasury Stock Shares	675.0K shares	675.0K shares	675.0K shares
Shareholders Equity	$28.31M	$46.50M	$23.31M
YoY Change
Total Liabilities & Shareholders Equity	$80.28M	$92.29M	$61.45M
YoY Change	29.47%	50.18%	117.91%

Cashflow Statement

Concept	2014 Q2	2014 Q1	2013 Q1
OPERATING ACTIVITIES
Net Income	-$19.94M	-$2.536M	-$16.49M
YoY Change	-470.03%	-84.62%	56.52%
Depreciation, Depletion And Amortization	$230.0K	$232.0K	$2.000K
YoY Change	475.0%	11500.0%	-95.24%
Cash From Operating Activities	-$12.97M	-$8.048M	-$5.331M
YoY Change	82.16%	50.97%	9.13%
INVESTING ACTIVITIES
Capital Expenditures	-$310.0K	$22.00K
YoY Change	-29.55%
Acquisitions		$0.00	$10.00M
YoY Change		-100.0%
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change	-100.0%
Cash From Investing Activities	-$310.0K	-$2.032M	-$10.09M
YoY Change	-338.46%	-79.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00	$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net		$3.000K
YoY Change
Cash From Financing Activities	20.00K	$14.72M	$92.00K
YoY Change	-99.81%	15900.0%	-95.73%
NET CHANGE
Cash From Operating Activities	-12.97M	-$8.048M	-$5.331M
Cash From Investing Activities	-310.0K	-$2.032M	-$10.09M
Cash From Financing Activities	20.00K	$14.72M	$92.00K
Net Change In Cash	-13.26M	$4.640M	-$15.33M
YoY Change	-485.47%	-130.28%	460.98%
FREE CASH FLOW
Cash From Operating Activities	-$12.97M	-$8.048M	-$5.331M
Capital Expenditures	-$310.0K	$22.00K
Free Cash Flow	-$12.66M	-$8.070M	-$5.331M
YoY Change	89.52%	51.38%	9.13%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q1	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	1548000	USD
CY2014Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	91000	USD
CY2014Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1574000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2660000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3683000	USD
CY2014Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1466000	USD
CY2014Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9793000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8667000	USD
CY2014Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	890000	USD
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	713000	USD
CY2013Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	158000	USD
CY2014Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	417000	USD
CY2014Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	231753000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	188600000	USD
CY2014Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	75000	USD
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	364000	USD
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1684000	USD
CY2013Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19408000	shares
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	22482000	shares
CY2013Q4	us-gaap	Assets Assets	87976000	USD
CY2014Q1	us-gaap	Assets Assets	92290000	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	55779000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	53455000	USD
CY2013Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	0.35	shares
CY2013Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	2.47
CY2013Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	2.50
CY2014Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	6000	USD
CY2013Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	6000	USD
CY2014Q1	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	23000	USD
CY2013Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	26000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47787000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52427000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32807000	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17481000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-15326000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4640000	USD
CY2014Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	9560000	shares
CY2013Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	14850000	shares
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	22038000	shares
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	110100701	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	118700812	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	118025812	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	109425701	shares
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	11000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	10000	USD
CY2014Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</font><font style="font-family:inherit;font-size:10pt;"> — Financial instruments that potentially subject the company to significant concentrations of credit risk consist principally of cash and cash equivalents. The company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the company’s cash equivalents were invested in money market mutual funds. The company’s investment policy does not allow investment in any debt securities rated less than “investment grade” by national ratings services. The company has not experienced any losses on its deposits of cash and cash equivalents.</font></div></div>
CY2013Q1	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
CY2014Q1	us-gaap	Cost Of Revenue CostOfRevenue	331000	USD
CY2014Q1	us-gaap	Costs And Expenses CostsAndExpenses	14022000	USD
CY2013Q1	us-gaap	Costs And Expenses CostsAndExpenses	6611000	USD
CY2013Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0845
CY2014Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	0	USD
CY2013Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-2762000	USD
CY2014Q1	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	-5053000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	-5053000	USD
CY2013Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	115000	USD
CY2014Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	104000	USD
CY2014Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	232000	USD
CY2013Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1999000	USD
CY2014Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1124000	USD
CY2013Q2	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0.0000
CY2013Q2	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P7Y
CY2013Q2	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.7534
CY2013Q2	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0120
CY2013Q4	us-gaap	Goodwill Goodwill	5898000	USD
CY2014Q1	us-gaap	Goodwill Goodwill	5898000	USD
CY2013Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2762000	USD
CY2014Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1086000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	147000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2217000	USD
CY2013Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	440000	USD
CY2014Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1026000	USD
CY2014Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-28000	USD
CY2013Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-74000	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-325000	USD
CY2014Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2013Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	1000	USD
CY2013Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	5000	USD
CY2014Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-314000	USD
CY2013Q1	us-gaap	Interest Paid InterestPaid	0	USD
CY2014Q1	us-gaap	Interest Paid InterestPaid	-211000	USD
CY2013Q4	us-gaap	Interest Payable Current InterestPayableCurrent	70000	USD
CY2014Q1	us-gaap	Interest Payable Current InterestPayableCurrent	70000	USD
CY2014Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	88000	USD
CY2013Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	116000	USD
CY2014Q1	us-gaap	Inventory Net InventoryNet	358000	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	386000	USD
CY2014Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	270000	USD
CY2013Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	270000	USD
CY2014Q1	us-gaap	Liabilities Liabilities	45786000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	82090000	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	92290000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	87976000	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	26840000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	62447000	USD
CY2014Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	3102000	USD
CY2013Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2149000	USD
CY2014Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	6883000	USD
CY2013Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	7743000	USD
CY2013Q1	us-gaap	Marketable Securities MarketableSecurities	9709000	USD
CY2014Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	0	USD
CY2013Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-7031000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14720000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	92000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2032000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10087000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5331000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8048000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-2536000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-9293000	USD
CY2013Q1	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	-5000000	USD
CY2014Q1	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	0	USD
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2536000	USD
CY2013Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-12055000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-11849000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6611000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2536000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-5024000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	7031000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax		USD
CY2014Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2013Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	2762000	USD
CY2013Q1	us-gaap	Other Income OtherIncome	-446000	USD
CY2014Q1	us-gaap	Other Income OtherIncome	-165000	USD
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	9313000	USD
CY2013Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5444000	USD
CY2014Q1	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	2010000	USD
CY2013Q1	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	USD
CY2014Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2013Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	10086000	USD
CY2013Q4	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	10086000	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22000	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2014Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2014Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2014Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2014Q1	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1399000	USD
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1328000	USD
CY2014Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reclassifications</font><font style="font-family:inherit;font-size:10pt;"> — Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share.</font></div></div>
CY2014Q1	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	5000	USD
CY2013Q1	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	1000	USD
CY2013Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	35000000	USD
CY2013Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	5200000	USD
CY2014Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4059000	USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	1542000	USD
CY2013Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	653000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	665000	USD
CY2014Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	3000	USD
CY2013Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	0	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5081000	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6770000	USD
CY2014Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	200000	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	200000	USD
CY2014Q1	us-gaap	Sales Discounts Services SalesDiscountsServices	0	USD
CY2013Q1	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
CY2014Q1	us-gaap	Sales Revenue Net SalesRevenueNet	2173000	USD
CY2013Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1530000	USD
CY2014Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6830000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1623000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	364000	USD
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7749
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7853
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0206
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0112
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4142000	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.73
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	13192000	USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	75000	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	80000	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.19
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.16
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3718000	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9848000	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13159000	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.73
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.25
CY2014Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4059000	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	46504000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	5886000	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5886000	USD
CY2014Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	46504000	USD
CY2014Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.30
CY2014Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.13
CY2014Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.48
CY2013Q3	us-gaap	Share Price SharePrice	2.00
CY2013Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2014Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2013Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	17500000	shares
CY2014Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3316000	shares
CY2014Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	37419000	USD
CY2014Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	53000	USD
CY2013Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	675000	shares
CY2014Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	675000	shares
CY2014Q1	us-gaap	Treasury Stock Value TreasuryStockValue	3849000	USD
CY2013Q4	us-gaap	Treasury Stock Value TreasuryStockValue	3849000	USD
CY2014Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Uses of Estimates in Preparation of Financial Statements</font><font style="font-family:inherit;font-size:10pt;"> — The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</font></div></div>
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	116244209	shares
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	83002323	shares
CY2013Q1	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	-5003000	USD
CY2014Q1	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	9792000	USD
CY2013Q1	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	-443000	USD
CY2014Q1	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	-166000	USD
CY2013Q2	gale	Classof Warrantor Right Term ClassofWarrantorRightTerm	P7Y
CY2013Q1	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	443000	USD
CY2014Q1	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	166000	USD
CY2014Q1	gale	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	-9792000	USD
CY2014Q1	gale	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	5590000	shares
CY2013Q2	gale	Classof Warrantor Right Average Market Price Used For Exercise Price ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice	P20D
CY2014Q1	gale	Classof Warrantor Right Granted ClassofWarrantorRightGranted	300000	shares
CY2014Q1	gale	Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan	708000	shares
CY2014Q1	gale	Common Stock Issued In Connection With Espp CommonStockIssuedInConnectionWithEspp	-53000	USD
CY2013Q1	gale	Common Stock Issued In Connection With Espp CommonStockIssuedInConnectionWithEspp	-38000	USD
CY2013Q4	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	6821000	USD
CY2014Q1	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	6987000	USD
CY2013Q4	gale	Contract Research Payable ContractResearchPayable	3109000	USD
CY2014Q1	gale	Contract Research Payable ContractResearchPayable	4765000	USD
CY2013Q2	gale	Debt Instrument Cash Facility Fee DebtInstrumentCashFacilityFee	0.01
CY2013Q2	gale	Debt Instrument Cash Final Payment DebtInstrumentCashFinalPayment	0.055
CY2013Q2	gale	Debt Instrument Term DebtInstrumentTerm	P30M
CY2013Q2	gale	Debt Instrument Term Interest Only DebtInstrumentTermInterestOnly	P12M
CY2013Q4	gale	Deficit Accumulated During Developmental Stage DeficitAccumulatedDuringDevelopmentalStage	-178875000	USD
CY2014Q1	gale	Deficit Accumulated During Developmental Stage DeficitAccumulatedDuringDevelopmentalStage	-181411000	USD
CY2014Q1	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts	10068000	USD
CY2013Q1	gale	Net Proceeds From Exercise Of Common Stock Warrants NetProceedsFromExerciseOfCommonStockWarrants	54000	USD
CY2013Q1	gale	Miscellaneous Other Income Expense MiscellaneousOtherIncomeExpense	-3000	USD
CY2014Q1	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition	P2Y9M4D
CY2014Q1	gale	Estimated Annualized Forfeiture Rate For Options Granted To Employees EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees	0.15
CY2014Q1	gale	Estimated Annualized Forfeiture Rate For Options Granted To Senior Management EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement	0.08
CY2014Q1	gale	Fair Value Of Warrants Exercised FairValueOfWarrantsExercised	-26808000	USD
CY2013Q4	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	48965000	USD
CY2014Q1	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	12365000	USD
CY2013Q4	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	48965000	USD
CY2014Q1	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	12365000	USD
CY2013Q2	gale	Fair Valueof Warrants Grantedper Share FairValueofWarrantsGrantedperShare	1.93
CY2013Q4	gale	Gale401rights GALE401rights	0	USD
CY2014Q1	gale	Gale401rights GALE401rights	2110000	USD
CY2013Q4	gale	In Process Research Development InProcessResearchDevelopment	12864000	USD
CY2014Q1	gale	In Process Research Development InProcessResearchDevelopment	12864000	USD
CY2014Q1	gale	Loss On Warrant Exchange LossOnWarrantExchange	-9792000	USD
CY2013Q1	gale	Loss On Warrant Exchange LossOnWarrantExchange	5003000	USD
CY2014Q1	gale	Maximum Maturity Period To Consider All Highly Liquid Debt Instruments As Cash And Cash Equivalents MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents	P90D
CY2014Q1	gale	Miscellaneous Other Income Expense MiscellaneousOtherIncomeExpense	1000	USD
CY2014Q1	gale	Net Proceeds From Exercise Of Common Stock Warrants NetProceedsFromExerciseOfCommonStockWarrants	10611000	USD
CY2014Q1	gale	Numberof Commerical Products NumberofCommericalProducts	1	products
CY2013Q2	gale	Numberof Days Averagedfor Exercise Price NumberofDaysAveragedforExercisePrice	P20D
CY2014Q1	gale	Numberof Dosing Strengths NumberofDosingStrengths	6	dosing_strength
CY2013Q3	gale	Numberof Shares Per Unit NumberofSharesPerUnit	1	shares
CY2014Q1	gale	Options Reserved For Future Issuance Under Companies Incentive Plan OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan	1922000	shares
CY2014Q1	gale	Patient Assistance Program Current PatientAssistanceProgramCurrent	2527000	USD
CY2013Q4	gale	Patient Assistance Program Current PatientAssistanceProgramCurrent	2618000	USD
CY2013Q3	gale	Proceeds From Issuanceor Saleof Equity Net Underwriting Discounts Commissionsand Offering Expenses ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses	37500000	USD
CY2014Q1	gale	Reclassification Of Warrant Liability Upon Exercise ReclassificationOfWarrantLiabilityUponExercise	26808000	USD
CY2013Q1	gale	Reclassification Of Warrant Liability Upon Exercise ReclassificationOfWarrantLiabilityUponExercise	124000	USD
CY2013Q4	gale	Sales And Distributions Rights SalesAndDistributionsRights	14979000	USD
CY2014Q1	gale	Sales And Distributions Rights SalesAndDistributionsRights	14882000	USD
CY2014Q1	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue	28000	USD
CY2014Q1	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue	0	USD
CY2013Q2	gale	Warrants Granted Numberof Shares WarrantsGrantedNumberofShares	182186	shares
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001390478
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	118025812	shares
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	Galena Biopharma, Inc.
CY2014Q1	dei	Trading Symbol TradingSymbol	GALE

Files In Submission

Name	View Source	Status
0001390478-14-000024-index-headers.html	Edgar Link	pending
0001390478-14-000024-index.html	Edgar Link	pending
0001390478-14-000024.txt	Edgar Link	pending
0001390478-14-000024-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
gale-20140331.xml	Edgar Link	completed
gale-20140331.xsd	Edgar Link	pending
gale-20140331x10q.htm	Edgar Link	pending
gale-20140331xex101.htm	Edgar Link	pending
gale-20140331xex311.htm	Edgar Link	pending
gale-20140331xex312.htm	Edgar Link	pending
gale-20140331xex321.htm	Edgar Link	pending
gale-20140331_cal.xml	Edgar Link	unprocessable
gale-20140331_def.xml	Edgar Link	unprocessable
gale-20140331_lab.xml	Edgar Link	unprocessable
gale-20140331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

2014 Q2 Form 10-Q Financial Statement

#000139047814000024 Filed on May 06, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS SELLAS Life Sciences Group, Inc. Stock $sls

2014 Q2 Form 10-Q Financial Statement

#000139047814000024 Filed on May 06, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls